Gene · 2046
EPHA8: EPH receptor A8
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. EPHA8: EPH receptor A8. Genes, record 2046. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2046
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P29322 | Ephrin type-A receptor 8 | 1,005 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents49
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 45084 | P29322 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 131 | P29322 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 107 | P29322 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 4821 | P29322 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1419 | P29322 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6275 | P29322 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1419 | P29322 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6275 | P29322 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 107 | P29322 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 131 | P29322 | Espacenet |
1 to 10 of 49
See all 49 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| VANDETANIB | CHEMBL24828 | Ephrin receptor inhibitor | INHIBITOR |
Source ChEMBL
Trials97
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06482086 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT04211337 | VANDETANIB | PHASE3 | 2024-06-13 | ClinicalTrials.gov |
| NCT03630120 | VANDETANIB | PHASE2 | 2021-01-22 | ClinicalTrials.gov |
| NCT03291379 | VANDETANIB | EARLY_PHASE1 | 2021-02-03 | ClinicalTrials.gov |
| NCT02638428 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT02530411 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT02495103 | VANDETANIB | PHASE1/PHASE2 | 2021-01-26 | ClinicalTrials.gov |
| NCT02299999 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT02117167 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT02109250 | VANDETANIB | ClinicalTrials.gov |
1 to 10 of 97
See all 97 trialsNIH grants1,520
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | EPHA8 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 10 | 2025 |
| R35GM118062 | Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics | 9 | 2025 |
| RM1HG009490 | Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human Disease | 9 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P30CA023168 | Cancer Center Support Grant | 4 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 4 | 2025 |
| P30CA023074 | University of Arizona Cancer Center - Cancer Center Support Grant | 3 | 2025 |
| T32CA009476 | Cancer Biology Training Program | 3 | 2025 |
| P01AI091580 | Defining the Unique Properties of the Distinct Signaling Machinery Used by the TCR | 2 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 2 | 2025 |
1 to 10 of 1,520Source NIH's project files
See all 1,520 nih grantsPapers2,828
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| JAK3 regulates PIP5K expression, promotes PIP2 generation and Ca2+ driven platelet activation in arterial thrombosis. | Blood | 2026 | 42766692 | PubTator, text mining | PubMed |
| SASH1 as a Context-Dependent Multi-Docking Scaffold Linking Receptor Signaling to Cytoskeletal Dynamics. | Int J Mol Sci | 2026 | 42589701 | PubTator, text mining | PubMed |
| Burden of rare genetic variants in genes associated with cancer among Malawian cervical cancer patients. | Afr J Lab Med | 2026 | 42266196 | PubTator, text mining | PubMed |
| Combining network pharmacology and experimental validation to study the action and mechanism of brusatol against lung adenocarcinoma. | Sci Rep | 2026 | 41933050 | PubTator, text mining | PubMed |
| Systems biology analysis uncovers a ROS-associated gene signature and immunomodulatory role of CLEC4E in ischemic stroke. | PLoS One | 2026 | 41805714 | PubTator, text mining | PubMed |
| lncRNAs: key player in Aβ deposition. | RNA Biol | 2026 | 41784271 | PubTator, text mining | PubMed |
| Identification of Novel Extracellular-Signal-Regulated Kinase 2 Inhibitors Through Machine Learning-Driven De Novo Design, Molecular Docking, and Free-Energy Perturbation. | Pharmaceuticals (Basel) | 2026 | 41754877 | PubTator, text mining | PubMed |
| Frags2Drugs: A Novel In Silico Fragment-Based Approach to the Discovery of Kinase Inhibitors. | Pharmaceuticals (Basel) | 2026 | 41754848 | PubTator, text mining | PubMed |
Epigenetic Landscape of Female Infertility: An Integrated Bioinformatics Perspective on DNA Methylation, MicroRNAs, and Gene Regulatory Networks Across PCOS, Endometriosis, and Diminished Ovarian Reserve. | Int J Mol Sci | 2026 | 41751922 | PubTator, text mining | PubMed |
| CRISPR-associated transposon for programmable viral vector engineering and prime editing. | Nucleic Acids Res | 2026 | 41728946 | PubTator, text mining | PubMed |
1 to 10 of 2,828
See all 2,828 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2046
GET https://conductscience.org/api/genes/v1/2046/patents?page=2